Angiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 17, Issue 4, 2011, Pages 963-970

  Oikonomou, Konstantinos A ^a   Kapsoritakis, Andreas N ^a   Kapsoritaki, Anastasia I ^a   Manolakis, Anastassios C ^a   Tiaka, Elisavet K ^a   Tsiopoulos, Fotios D ^a   Tsiompanidis, Ilias A ^a   Potamianos, Spiros P ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Angiogenin; Angiopoietin 1; Angiopoietin 2; Endostatin; Inflammatory bowel disease

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANTIBIOTIC AGENT; C REACTIVE PROTEIN; ENDOSTATIN; SERUM AMYLOID A; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ANGIOGENIN BLOOD LEVEL; ANGIOPOIETIN 1 BLOOD LEVEL; ANGIOPOIETIN 2 BLOOD LEVEL; ARTICLE; BLOOD LEVEL; COLON; CONTROLLED STUDY; CROHN DISEASE; ENDOSTATIN BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANGIOPOIETIN-1; ANGIOPOIETIN-2; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; ENDOSTATINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; RIBONUCLEASE, PANCREATIC; YOUNG ADULT;

EID: 79952481259     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21410     Document Type: Article

References (59)

1. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 2000;52:237-268. (Pubitemid 30368433)
2. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol. 2001;61:253-270. (Pubitemid 32126663)
3. Koutroubakis IE, Tsiolakidou G, Karmiris K, et al. Role of angiogenesis in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:515-523.
4. Deban L, Correale C, Vetrano S, et al. Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades. Am J Pathol. 2008;172:1457-1466. (Pubitemid 351793339)
5. Griga T, Tromm A, Spranger J, et al. Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease. Scand J Gastroenterol. 1998;33:504-508. (Pubitemid 28277250)
6. Kanazawa S, Tsunoda T, Onuma E, et al. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol. 2001;96:822-828. (Pubitemid 32240738)
7. Di Sabatino A, Ciccocioppo R, Armellini E, et al. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease. Inflamm Bowel Dis. 2004;10:573-577. (Pubitemid 39276464)
8. Ferrante M, Pierik M, Henckaerts L, et al. The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:870-878. (Pubitemid 44352714)
9. Sandor Z, Deng XM, Khomenko T, et al. Altered angiogenic balance in ulcerative colitis: a key to impaired healing?Biochem Biophys Res Commun. 2006;350:147-150.
10. Pousa ID, Maté J, Salcedo-Mora X, et al. Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohn's disease patients. Inflamm Bowel Dis. 2008;14:61-67. (Pubitemid 351196870)
11. Kapsoritakis A, Sfiridaki A, Maltezos E, et al. Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis. 2003;18:418-422. (Pubitemid 37062733)
12. Magro F, Araujo F, Pereira P, et al. Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease. Dig Dis Sci. 2004;49:1265-1274. (Pubitemid 39178099)
13. Strydom DJ. The angiogenins. Cell Mol Life Sci. 1998;54:811-824. (Pubitemid 28425313)
14. Badet J. Angiogenin, a potent mediator of angiogenesis. Biological, biochemical and structural properties. Pathol Biol (Paris). 1999;47:345-351.
15. Shapiro R, Riordan JF, Vallee BL. Characteristic ribonucleolytic activity of human angiogenin. Biochemistry. 1986;25:3527-3532 [Erratum 1986;25:6730].
16. King TV, Vallee BL. Neovascularisation of the meniscus with angiogenin. An experimental study in rabbits. J Bone Joint Surg Br. 1991;73:587-590.
17. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55-60. (Pubitemid 27450643)
18. Loughna S, Sato TN. Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol. 2001;20:319-325. (Pubitemid 32846717)
19. Visconti RP, Richardson CD, Sato TN. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci USA. 2002;99:8219-8224. (Pubitemid 34651033)
20. Asahara T, Chen D, Takahashi T, et al. Tie2 receptor ligands, angio-poietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res. 1998;83:233-240. (Pubitemid 28371312)
21. Takakura N, Watanabe T, Suenobu S, et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell. 2000;102:199-209.
22. Dallabrida SM, Ismail N, Oberle JR, et al. Angiopoietin-1 promotes cardiac and skeletal myocyte survival through integrins. Circ Res. 2005;96:e8-24.
23. Li JJ, Huang YQ, Basch R, et al. Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost. 2001;85:204-206. (Pubitemid 32140561)
24. Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell. 2002;3:411-423.
25. Kim I, Kim JH, Moon SO et al. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene. 2000;19:4549-4552.
26. Fiedler U, Krissl T, Koidl S, et al. Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem. 2003;278:1721-1727. (Pubitemid 36801406)
27. Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res. 2006;312:594-607. (Pubitemid 43290336)
28. Mundhenke C, Thomas JP, Wilding G, et al. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res. 2001;7:3366-3374. (Pubitemid 33069967)
29. Kisker O, Becker CM, Prox D, et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001;61:7669-7674. (Pubitemid 32995064)
30. Ren B, Höti N, Rabasseda X, et al. The antiangiogenic and therapeutic implications of endostatin. Methods Find Exp Clin Pharmacol. 2003;25:215-224. (Pubitemid 36604240)
31. Schuch G, Heymach JV, Nomi M, et al. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res. 2003;63:8345-8350. (Pubitemid 37549488)
32. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285. (Pubitemid 28015876)
33. Hajitou A, Grignet C, Devy L, et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J. 2002;16:1802-1804.
34. Berger AC, Feldman AL, Gnant MF, et al. The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. J Surg Res. 2000;91:26-31. (Pubitemid 30340891)
35. Li Q, Olsen BR. Increased angiogenic response in aortic explants of collagen XVIII/endostatin-null mice. Am J Pathol. 2004;165:415-424. (Pubitemid 38971372)
36. van Hensbergen Y, Broxterman HJ, Hanemaaijer R, et al. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin Cancer Res. 2002;8:3747-3754. (Pubitemid 35424765)
37. Hebbar M, Peyrat JP, Hornez L, et al. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum. 2000;43:889-893.
38. Koutroubakis IE, Xidakis C, Karmiris K, et al. Serum angiogenin in inflammatory bowel disease. Dig Dis Sci. 2004;49:1758-1762. (Pubitemid 40228533)
39. Koutroubakis IE, Xidakis C, Karmiris K, et al. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease. Eur J Clin Invest. 2006;36:127-132.
40. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29-32. (Pubitemid 28335486)
41. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6; discussion 16-19.
42. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
43. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-86. (Pubitemid 19032930)
44. Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006;130:2060-2073. (Pubitemid 43816964)
45. Distler JH, Hirth A, Kurowska-Stolarska M, et al. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med. 2003;47:149-161. (Pubitemid 37279152)
46. Lioté F, Champy R, Moenner M, et al. Elevated angiogenin levels in synovial fluid from patients with inflammatory arthritis and secretion of angiogenin by cultured synovial fibroblasts. Clin Exp Immunol. 2003;132:163-168. (Pubitemid 36422602)
47. Martin JW, Mousa SS, Shaker O, et al. The multiple faces of nicotine and its implications in tissue and wound repair. Exp Dermatol. 2009;18:497-505.
48. Wu WK, Cho CH. The pharmacological actions of nicotine on the gastrointestinal tract. J Pharmacol Sci. 2004;94:348-358.
49. Kishimoto K, Liu S, Tsuji T, et al. Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene. 2005;24:445-456. (Pubitemid 40188592)
50. Tschesche H, Kopp C, Hörl WH, et al. Inhibition of degranulation of polymorphonuclear leukocytes by angiogenin and its tryptic fragment. J Biol Chem. 1994;269:30274-30280. (Pubitemid 24376498)
51. Matousek J, Soucek J, Ríha J, et al. Immunosuppressive activity of angiogenin in comparison with bovine seminal ribonuclease and pancreatic ribonuclease. Comp Biochem Physiol B Biochem Mol Biol. 1995;112:235-241.
52. Roviezzo F, Tsigkos S, Kotanidou A, et al. Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther. 2005;314:738-744. (Pubitemid 41043857)
53. Sturn DH, Feistritzer C, Mosheimer BA, et al. Angiopoietin affects neutrophil migration. Microcirculation. 2005;12:393-403. (Pubitemid 41122464)
54. Langenkamp E, Molema G. Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Cell Tissue Res. 2009;335:205-222.
55. Abdollahi A, Hlatky L, Huber PE. Endostatin: the logic of anti-angiogenic therapy. Drug Resist Updat. 2005;8:59-74.
56. Benezra R, Rafii S. Endostatin's endpoints - deciphering the endostatin antiangiogenic pathway. Cancer Cell. 2004;5:205-206. (Pubitemid 38402111)
57. Wickström SA, Alitalo K, Keski-Oja J. Endostatin signaling and regulation of endothelial cell-matrix interactions. Adv Cancer Res. 2005;94:197-229. (Pubitemid 41202366)
58. Funatsu H, Yamashita H, Noma H, et al. Stimulation and inhibition of angiogenesis in diabetic retinopathy. Jpn J Ophthalmol. 2001;45:577-584. (Pubitemid 34081770)
59. Nardo LG. Vascular endothelial growth factor expression in the endometrium during the menstrual cycle, implantation window and early pregnancy. Curr Opin Obstet Gynecol. 2005;17:419-423. (Pubitemid 41044413)